Latest News for: parp

Edit

Unexpected Cancer Drug Combo Shows Stronger Results Against Ovarian Tumors

Mega Doctor News 12 Feb 2026
A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better.
Edit

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer

PNAS 27 Jan 2026
SignificanceWhether patients with homologous recombination ...
Edit

Whole-genome sequencing may optimize PARP inhibitor use (Cornell University)

Public Technologies 14 Jan 2026
Tumors with this defect are vulnerable to PARP inhibitors, which further disrupt DNA repair, causing cancer cells to accumulate DNA damage and die ... if patients will benefit from PARP inhibitors.
Edit

Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel ...

Norfolk Daily News 20 Dec 2025
FDA approval is based on the positive results of TRITON3, a ...
Edit

Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial

PR Newswire 19 Dec 2025
The approval is supported by the pivotal TRITON3 Phase 3 trial, which demonstrated that Rubraca is the first and only PARP inhibitor to exceed the efficacy of docetaxel in a direct, head-to-head ...
Edit

Medicalgorithmics has signed an agreement with PARP. The company will receive PLN 9.4 million for the development of a project based on VCAST technology (Medicalgorithmics SA)

Public Technologies 18 Dec 2025
Medicalgorithmics, a Warsaw Stock Exchange-listed developer of globally innovative AI solutions for the cardiology industry, has signed an agreement with PARP to support its innovative Kardiobeat.CT project.
  • 1

Article Search

tools
×
×
×
×